Waya Health

WAYA Health operates at the intersection of digital health, medical devices, virtual reality, and extended reality. Its differentiation is a broad healthcare platform approach: the company combines enterprise content and device management with clinical applications for rehabilitation, fall-risk assessment, procedural comfort, pediatrics, and senior care. That breadth contrasts with narrower immersive-health products focused only on pain distraction, behavioral health, or therapy. The company’s clinician-founded positioning may support practical workflow design, while its stated use of artificial intelligence and a unified XR architecture suggests an ambition to consolidate multiple applications within one infrastructure layer. The 2023 Reimagine Well partnership and the 2023 patent grant provide evidence of ecosystem engagement and proprietary development, respectively. At the same time, the small disclosed employee range of one to ten people indicates a substantially smaller operating footprint than scaled immersive-health vendors and hospital-platform providers. WAYA Health therefore appears to be an early-stage specialist pursuing differentiated clinical applications, but its competitive standing remains difficult to quantify.

WAYA Health was founded in 2016 and has developed from a clinician-founded venture into a portfolio company with enterprise software, medical-device, and immersive-care applications. Joseph Morgan has served as Founder and President since September 2016. A notable inflection point came on Mar 28, 2023, when an XR health platform, system and method associated with Wellovate LLC received U.S. Patent 11,961,197 B1. This indicates progression from concept development toward formal intellectual-property protection. Another milestone followed on Aug 21, 2023 with the Reimagine Well partnership, suggesting an effort to extend adoption through external healthcare relationships. The product set now covers rehabilitation, fall assessment, procedural support, pediatric care, and senior care, which could allow cross-selling across hospitals, therapy providers, and residential settings. The trajectory is therefore best characterized as product-led and partnership-supported, with evidence of technical maturation but limited proof of organizational or commercial scaling through Oct 3, 2026.